Sutee Yoksan mainly focuses on Dengue fever, Immunology, Virology, Dengue virus and Dengue vaccine. His studies deal with areas such as Secondary infection, Viremia, Internal medicine, Flavivirus and Seroconversion as well as Dengue fever. His research investigates the connection between Immunology and topics such as Attenuated vaccine that intersect with issues in Headaches and Recombinant virus.
In Virology, he works on issues like Immunogenicity, which are connected to Neutralizing antibody. His Dengue virus research is multidisciplinary, incorporating perspectives in Outbreak response, Antibody, Immunoglobulin M and Immune system. His Vaccination study integrates concerns from other disciplines, such as Adverse effect, Serotype and Reactogenicity.
Sutee Yoksan mainly investigates Virology, Dengue fever, Immunology, Dengue virus and Japanese encephalitis. Sutee Yoksan has included themes like Antibody and Antigen in his Virology study. Sutee Yoksan is involved in the study of Dengue fever that focuses on Dengue vaccine in particular.
Immunology connects with themes related to Adverse effect in his study. His Antibody-dependent enhancement study in the realm of Dengue virus connects with subjects such as Original antigenic sin. In his study, which falls under the umbrella issue of Japanese encephalitis, Seroprevalence is strongly linked to Plaque reduction neutralization test.
His scientific interests lie mostly in Virology, Dengue fever, Dengue virus, Immunology and Japanese encephalitis. Sutee Yoksan focuses mostly in the field of Virology, narrowing it down to topics relating to Antibody and, in certain cases, Antigen. His Dengue fever research is multidisciplinary, incorporating elements of Transmission, Thalassemia, Immune system and Serum samples.
His Dengue virus research is multidisciplinary, relying on both Capture elisa, Serotype, Igm elisa, Flavivirus and In vivo. His Japanese encephalitis study combines topics in areas such as Titer, Plaque reduction neutralization test, Seroprevalence and Zika virus. His Japanese encephalitis vaccine study incorporates themes from Booster dose, Adverse effect, Immunogenicity, Vaccination and Seroconversion.
His primary areas of investigation include Virology, Dengue virus, Immunology, Dengue fever and Virus. His study in Virology is interdisciplinary in nature, drawing from both Antibody and Antigen. His biological study focuses on Dengue vaccine.
His Dengue fever research includes elements of CD14, Immune system and Monocyte. The study incorporates disciplines such as Lipogenesis, Fatty acid synthase, Gene expression and Microbiology in addition to Virus. His Japanese encephalitis research focuses on Zika virus and how it relates to Flavivirus, Serum samples and Transmission.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Dengue: a continuing global threat
Maria G. Guzman;Scott B. Halstead;Harvey Artsob;Philippe Buchy.
Nature Reviews Microbiology (2010)
Evaluation of diagnostic tests: dengue.
Rosanna W. Peeling;Rosanna W. Peeling;Harvey Artsob;Jose Luis Pelegrino;Philippe Buchy.
Nature Reviews Microbiology (2010)
A variant in the CD209 promoter is associated with severity of dengue disease.
Anavaj Sakuntabhai;Anavaj Sakuntabhai;Chairat Turbpaiboon;Chairat Turbpaiboon;Isabelle Casadémont;Ampaiwan Chuansumrit.
Nature Genetics (2005)
Diagnostic accuracy of NS1 ELISA and lateral flow rapid tests for dengue sensitivity, specificity and relationship to viraemia and antibody responses.
Vu Thi Ty Hang;Nguyen Minh Nguyet;Vianney Tricou.
PLOS Neglected Tropical Diseases (2009)
Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
Thomas P. Monath;Farshad Guirakhoo;Richard Nichols;Sutee Yoksan.
The Journal of Infectious Diseases (2003)
Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses.
Arunee Sabchareon;Jean Lang;Pornthep Chanthavanich;Sutee Yoksan.
American Journal of Tropical Medicine and Hygiene (2002)
Clinical proof of principle for ChimeriVax™: recombinant live, attenuated vaccines against flavivirus infections
Thomas P Monath;Karen McCarthy;Philip Bedford;Casey T Johnson.
Vaccine (2002)
Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.
Farshad Guirakhoo;Scott Kitchener;Dennis Morrison;Remi Forrat.
Human Vaccines (2006)
Evaluation of commercially available anti-dengue virus immunoglobulin M tests.
Elizabeth A Hunsperger;Sutee Yoksan;Philippe Buchy;van Vinh Chau Nguyen.
Emerging Infectious Diseases (2009)
Rapid and massive virus specific plasmablast responses during acute dengue virus infection in humans
Jens Wrammert;Nattawat Onlamoon;Rama Akondy;Guey Chuen 'Oscar' Perng.
Journal of Virology (2012)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Georgetown University
Sanofi (France)
National Science and Technology Development Agency
Mahidol University
University College London
Uniformed Services University of the Health Sciences
Instituto de Medicina Tropical “Pedro Kourí”
London School of Hygiene & Tropical Medicine
Wellcome Trust
University of Helsinki
Imec
University College London
Cornell University
Brandeis University
Dartmouth College
University of Algarve
KU Leuven
Lund University
Northwest Research Associates
University of Florida
Rutgers, The State University of New Jersey
Leiden University Medical Center
New York University
University of Michigan–Ann Arbor
Cleveland Clinic
University College London